Stock TRVI TREVI THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Trevi Therapeutics, Inc.

Equities

TRVI

US89532M1018

Market Closed - Nasdaq
Other stock markets
 03:59:46 2024-06-04 pm EDT 		5-day change 1st Jan Change
2.61 USD +2.35% Intraday chart for Trevi Therapeutics, Inc. +1.95% +94.78%
May. 07 Transcript : Trevi Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
May. 07 Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on Trevi Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d99515f58979d951e2f7be4db7577e4._gxKeYZfyjQKWaGaY7agN5xbJvp7Ldx0Tig3fXgXY2U.kWIZEuoHjHNOGOz3N4_tDqQfFYkBb5c4BkJaPksvKiatIXgwzSaHfD5v4A~5e04c61e81dcb0bbfdcd146581e498ab

Analyst Recommendations on Trevi Therapeutics, Inc.

B. Riley Starts Trevi Therapeutics at Buy With $6 PT, Views as Deep Value Play in Idiopathic Pulmonary Fibrosis Chronic Cough Space MT
JonesTrading Initiates Trevi Therapeutics at Buy With $7 Price Target MT
SVB Securities Starts Trevi Therapeutics at Outperform With $6 Price Target MT
Oppenheimer Adjusts Trevi Therapeutics Price Target to $9 From $12 Mainly on Higher Discount Rate, Maintains Outperform Rating MT
Needham Trims Price Target on Trevi Therapeutics to $8 From $10, Maintains Buy Rating MT
Oppenheimer Adjusts Trevi Therapeutics' Price Target to $12 From $10, Maintains Outperform Rating MT
Needham Adjusts Trevi Therapeutics' Price Target to $10 From $8, Reiterates Buy Rating MT
Trevi Therapeutics Rises After Oppenheimer Starts Coverage With Outperform Rating MT
Oppenheimer Starts Trevi Therapeutics at Outperform With $10 Price Target MT
Aegis Capital Initiates Trevi Therapeutics at Buy with $10 Price Target MT
Needham Adjusts Price Target on Trevi Therapeutics to $8 from $10, Keeps Buy Rating MT
TREVI THERAPEUTICS : Needham Adjusts Trevi Therapeutics' Price Target to $10 from $12, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.61 USD
Average target price
7.4 USD
Spread / Average Target
+183.52%
High Price Target
9 USD
Spread / Highest target
+244.83%
Low Price Target
6 USD
Spread / Lowest Target
+129.89%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Trevi Therapeutics, Inc.

B. Riley
JonesTrading Institutional Services
SVB Securities LLC
Oppenheimer
Needham & Co.
Aegis Capital

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TRVI Stock
  4. Consensus Trevi Therapeutics, Inc.